2018 HIV Drug Therapy HCV

A report on Erica Peter's presentation "Interactive Case Study: HIV-HCV and PWIDS"

Dr Erica Peters, a local Glasgow ID physician, has seen a disturbing rise in the incidence of HIV (133 in the last few years, 1/3 women) in the population of people who inject drugs in Glasgow: many are co-infected with HCV. This population poses challenges for decision-making on drug therapy given that many people in this population are both taking both prescribed and recreational drugs.

A report on Andrew Hill's presentation "Minimum prices of generic Hepatitis C direct acting antivirals fall below US$50"

Andrew outlines an alternative cost strategy for making the elimination of Hepatitis C (HCV) affordable. This talk complements the previous one by Margaret Hellard.

A report on Margaret Hellard's "Eliminating Hepatitis C by 2030: A public health perspective"

Margaret made a compelling case for a more concerted effort to be made worldwide for Hepatitis C ( HCV) to be eliminated. HCV is responsible for a similar number of deaths worldwide as HIV and TB, and more than are due to malaria. Yet, HCV is remarkable for now having a highly effective cure using Direct Acting Antivirals (DAAs), that can be achieved in 3 months and with minimal side effects.